RS54702B1 - PYRAZOLOCHINOLINE DERIVATIVES AS PDE9 INHIBITORS - Google Patents
PYRAZOLOCHINOLINE DERIVATIVES AS PDE9 INHIBITORSInfo
- Publication number
- RS54702B1 RS54702B1 RS20160232A RSP20160232A RS54702B1 RS 54702 B1 RS54702 B1 RS 54702B1 RS 20160232 A RS20160232 A RS 20160232A RS P20160232 A RSP20160232 A RS P20160232A RS 54702 B1 RS54702 B1 RS 54702B1
- Authority
- RS
- Serbia
- Prior art keywords
- group
- atom
- halogen
- atoms
- hydrogen atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161544860P | 2011-10-07 | 2011-10-07 | |
US201161550623P | 2011-10-24 | 2011-10-24 | |
US201161558110P | 2011-11-10 | 2011-11-10 | |
US201161580903P | 2011-12-28 | 2011-12-28 | |
PCT/JP2012/075748 WO2013051639A1 (ja) | 2011-10-07 | 2012-10-04 | ピラゾロキノリン誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
RS54702B1 true RS54702B1 (en) | 2016-08-31 |
Family
ID=48043792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20160232A RS54702B1 (en) | 2011-10-07 | 2012-10-04 | PYRAZOLOCHINOLINE DERIVATIVES AS PDE9 INHIBITORS |
Country Status (33)
Country | Link |
---|---|
US (2) | US8563565B2 (de) |
EP (1) | EP2769980B1 (de) |
JP (1) | JP5546693B2 (de) |
KR (1) | KR101943680B1 (de) |
CN (1) | CN103930423B (de) |
AR (1) | AR088235A1 (de) |
AU (1) | AU2012319549B2 (de) |
BR (1) | BR112014007912B1 (de) |
CA (1) | CA2861795C (de) |
CL (1) | CL2014000821A1 (de) |
CO (1) | CO6910200A2 (de) |
CY (1) | CY1117427T1 (de) |
DK (1) | DK2769980T3 (de) |
ES (1) | ES2568015T3 (de) |
HK (1) | HK1199018A1 (de) |
HR (1) | HRP20160273T1 (de) |
HU (1) | HUE028555T2 (de) |
IL (1) | IL231650A (de) |
IN (1) | IN2014CN02463A (de) |
JO (1) | JO3116B1 (de) |
ME (1) | ME02394B (de) |
MX (1) | MX358149B (de) |
MY (1) | MY167698A (de) |
PE (1) | PE20141557A1 (de) |
PL (1) | PL2769980T3 (de) |
RS (1) | RS54702B1 (de) |
RU (1) | RU2605096C2 (de) |
SG (1) | SG11201400717QA (de) |
SI (1) | SI2769980T1 (de) |
SM (1) | SMT201600108B (de) |
TW (1) | TWI562993B (de) |
WO (1) | WO2013051639A1 (de) |
ZA (1) | ZA201402439B (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2886885C (en) | 2011-10-10 | 2019-07-16 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
EP2982674B1 (de) * | 2013-04-05 | 2017-10-25 | Eisai R&D Management Co., Ltd. | Pyridinylpyrazolochinolinverbindung |
CA2907971C (en) | 2013-04-05 | 2020-12-29 | Eisai R&D Management Co., Ltd. | Salt of pyrazoloquinoline derivative, and crystal thereof |
GB201406486D0 (en) | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
WO2016021192A1 (en) * | 2014-08-08 | 2016-02-11 | Eisai R&D Management Co., Ltd. | Process for production of (s)-(tetrahydrofuran-3-yl)hydrazine |
EP4335497A3 (de) | 2015-07-07 | 2024-05-01 | H. Lundbeck A/S | Pde9-inhibitor mit imidazopyrazinon-rückgrat zur behandlung von peripheren erkrankungen |
WO2017046606A1 (en) * | 2015-09-18 | 2017-03-23 | Redx Pharma Plc | Antibacterial compounds |
CN107056690A (zh) * | 2017-03-22 | 2017-08-18 | 上海康鹏科技有限公司 | 一种6‑溴吡啶‑3‑甲醛的制备方法 |
CA3059539A1 (en) * | 2017-06-01 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising pde9 inhibitor |
BR112019023595A2 (pt) * | 2017-06-01 | 2020-05-26 | Eisai R&D Management Co., Ltd. | Agente terapêutico da demência combinando derivados de pirazoloquinolina e memantina |
TWI784006B (zh) * | 2017-06-01 | 2022-11-21 | 日商衛材R&D企管股份有限公司 | 含有吡唑并喹啉衍生物之路易氏體症治療劑 |
KR102627787B1 (ko) * | 2017-06-01 | 2024-01-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체와 도네페질을 병용한 치매 치료제 |
CN111630042A (zh) * | 2018-01-23 | 2020-09-04 | 巴斯夫欧洲公司 | 吡啶衍生物的卤化 |
KR20210053948A (ko) * | 2018-08-31 | 2021-05-12 | 이마라 인크. | 겸상 세포 질환의 치료를 위한 pde9 억제제 |
AU2020268409A1 (en) * | 2019-05-09 | 2021-11-25 | The Feinstein Institutes For Medical Research | Compounds for use in synthesis of peptidomimetics |
US11883461B2 (en) | 2019-05-09 | 2024-01-30 | The Feinstein Institutes For Medical Research | HMGB1 antagonist treatment of severe sepsis |
US11471507B2 (en) | 2019-05-09 | 2022-10-18 | The Feinstein Institutes For Medical Research | HMGB1 antagonist |
EP3966201A4 (de) | 2019-05-09 | 2023-01-18 | The Feinstein Institutes for Medical Research | Thiosemicarbazate und ihre verwendungen |
WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
CR20220584A (es) * | 2020-04-16 | 2023-02-15 | Incyte Corp | Inhibidores de kras tricíclicos fusionados |
US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
CA3188782A1 (en) | 2020-06-30 | 2022-01-06 | Bayer Aktiengesellschaft | Substituted heteroaryloxypyridines, the salts thereof and their use as herbicidal agents |
US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
US11939328B2 (en) | 2021-10-14 | 2024-03-26 | Incyte Corporation | Quinoline compounds as inhibitors of KRAS |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2426734C2 (ru) * | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
WO2005118583A1 (en) * | 2004-05-28 | 2005-12-15 | Millennium Pharmaceuticals, Inc. | 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors |
US8193356B2 (en) * | 2005-09-15 | 2012-06-05 | Aska Pharmaceutical Co., Ltd. | Heterocycle compound, and production process and application thereof |
JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
ES2599054T3 (es) * | 2006-12-13 | 2017-01-31 | Aska Pharmaceutical Co., Ltd. | Derivados de quinoxalina |
ATE540954T1 (de) | 2007-05-11 | 2012-01-15 | Pfizer | Aminoheterocyclische verbindungen |
UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
BRPI1009287A2 (pt) * | 2009-03-05 | 2019-09-24 | Astellas Pharma Inc | composto de quinoxalina |
MY156377A (en) | 2009-03-31 | 2016-02-15 | Boehringer Ingelheim Int | 1-heterocycl-1, 5-dihydro-pyrazolo [3 , 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
EA023493B1 (ru) | 2010-09-07 | 2016-06-30 | Астеллас Фарма Инк. | Производное пиразолохинолина |
JP6042060B2 (ja) * | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
-
2012
- 2012-10-04 AU AU2012319549A patent/AU2012319549B2/en active Active
- 2012-10-04 JO JOP/2012/0302A patent/JO3116B1/ar active
- 2012-10-04 DK DK12837953.4T patent/DK2769980T3/en active
- 2012-10-04 KR KR1020147008769A patent/KR101943680B1/ko active IP Right Grant
- 2012-10-04 SI SI201230501A patent/SI2769980T1/sl unknown
- 2012-10-04 PL PL12837953T patent/PL2769980T3/pl unknown
- 2012-10-04 MY MYPI2014700702A patent/MY167698A/en unknown
- 2012-10-04 RU RU2014112931/04A patent/RU2605096C2/ru active
- 2012-10-04 AR ARP120103702A patent/AR088235A1/es active IP Right Grant
- 2012-10-04 IN IN2463CHN2014 patent/IN2014CN02463A/en unknown
- 2012-10-04 PE PE2014000408A patent/PE20141557A1/es active IP Right Grant
- 2012-10-04 EP EP12837953.4A patent/EP2769980B1/de active Active
- 2012-10-04 WO PCT/JP2012/075748 patent/WO2013051639A1/ja active Application Filing
- 2012-10-04 ME MEP-2016-65A patent/ME02394B/de unknown
- 2012-10-04 CA CA2861795A patent/CA2861795C/en active Active
- 2012-10-04 RS RS20160232A patent/RS54702B1/en unknown
- 2012-10-04 HU HUE12837953A patent/HUE028555T2/en unknown
- 2012-10-04 MX MX2014003800A patent/MX358149B/es active IP Right Grant
- 2012-10-04 US US13/644,745 patent/US8563565B2/en active Active
- 2012-10-04 SG SG11201400717QA patent/SG11201400717QA/en unknown
- 2012-10-04 ES ES12837953.4T patent/ES2568015T3/es active Active
- 2012-10-04 BR BR112014007912-9A patent/BR112014007912B1/pt active IP Right Grant
- 2012-10-04 CN CN201280046653.2A patent/CN103930423B/zh active Active
- 2012-10-04 TW TW101136747A patent/TWI562993B/zh active
- 2012-10-04 JP JP2013537544A patent/JP5546693B2/ja active Active
-
2013
- 2013-06-11 US US13/914,898 patent/US20130296352A1/en not_active Abandoned
-
2014
- 2014-03-19 CO CO14059034A patent/CO6910200A2/es active IP Right Grant
- 2014-03-20 IL IL231650A patent/IL231650A/en active IP Right Grant
- 2014-04-02 ZA ZA2014/02439A patent/ZA201402439B/en unknown
- 2014-04-03 CL CL2014000821A patent/CL2014000821A1/es unknown
- 2014-12-08 HK HK14112316.6A patent/HK1199018A1/zh unknown
-
2016
- 2016-03-17 HR HRP20160273TT patent/HRP20160273T1/hr unknown
- 2016-04-12 CY CY20161100302T patent/CY1117427T1/el unknown
- 2016-04-14 SM SM201600108T patent/SMT201600108B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS54702B1 (en) | PYRAZOLOCHINOLINE DERIVATIVES AS PDE9 INHIBITORS | |
RS54183B1 (en) | PIRAZOLE DERIVATIVES | |
RS54175B1 (en) | BROMODOMEN INHIBITORS AND THEIR APPLICATION | |
RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
MX2009004920A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1. | |
RS52261B (en) | AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR | |
RS54048B1 (en) | PARASITICIDE COMPOUNDS OF DIHYDROISOXAZOLE | |
MX344276B (es) | Compuesto de piperidina novedoso o sal del mismo. | |
EA201890098A3 (ru) | Производное хинолона | |
RS54506B1 (en) | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | |
RS54708B1 (en) | ARYLETINYL DERIVATIVES | |
RS52514B (en) | DERIVATI AMINO NIKOTINSKE I IZONIKOTINSKE KISELINE KAO INHIBITORI DHODH | |
RS54840B1 (sr) | 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido(2,3-d)pirimidin-6-il)fenil)urea kao inhibitor raf kinaze za tretman kancera | |
RS51949B (en) | INHIBITORI KINAZE | |
RS52216B (en) | UNITS AND METHODS FOR FXR MODULATION | |
EP2597088A4 (de) | P2x4-rezeptor-antagonisten | |
RS54480B1 (en) | IMIDAZOPYRIDASINE AS ACT KINASE INHIBITORS | |
MY165585A (en) | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors | |
RS54526B1 (en) | USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS | |
MX2009011769A (es) | Derivados de piridona como inhibidores de mapk p38a. | |
RS54825B1 (sr) | Derivati azola | |
RS52964B (en) | 7-PIPERIDINOALKIL-3,4-DIHYDROKVINOLONE DERIVATIVE | |
IN2014DN07509A (de) | ||
RS52515B (en) | QUICKLY DISSOCATING DOPAMIN 2 RECEPTOR ANTAGONISTS | |
MX2016005993A (es) | Anfifilos biscationicos y triscationicos como agentes antimicrobianos. |